News | News By Subject | News by Disease News By Date | Search News

Hemophilia A News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
FDA Gives Thumbs Up to Bayer (BAY)'s Hemophilia A Drug Kovaltry     3/17/2016
FDA Green Lights Octapharma USA's NUWIQ for Hemophilia A     9/15/2015
Genentech (RHHBY)’s Hemophilia A Drug Gets Breakthrough Designation in Potential $11 Billion Market     9/10/2015
Biogen Idec (BIIB) Will Be Hiring in R&D After Around 20 Employees Leave Following Review     3/17/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Baxter International, Inc. (BAX)'s Hemophilia A Drug Obizur Wins FDA Approval     10/24/2014
Long-Acting Version Of Baxter International, Inc. (BAX)'s Hemophilia A Drug BAX 855 Succeeds In Study     8/21/2014
Baxter International, Inc. (BAX) Opens Its First State-Of-The-Art Biologics Facility In Asia     8/11/2014
FDA Approves Biogen, Inc.'s Hemophilia A Drug Eloctate     6/9/2014
FDA Approves Bayer HealthCare (BAY)'s Kogenate® FS Antihemophilic Factor VIII (Recombinant) For Routine Prophylaxis In Adults With Hemophilia A     5/12/2014
Bayer AG (BAYN.DE) To Inject $700 Million In Hemophilia A Drugs     3/11/2014
Bayer HealthCare Pharmaceuticals (BAYA.F)' Long-Acting Hemophilia Drug Shown To Be Effective     2/18/2014

News from Around the Web

Press Releases
Sangamo (SGMO) Presents Hemophilia A Program Data At The 2016 American Society of Hematology Meeting     12/6/2016
Alnylam (ALNY) Reports Positive Interim Clinical Results For Fitusiran From Ongoing Phase 2 Open Label Extension Study In Patients With Hemophilia A Or B Without Inhibitors     12/5/2016
Swedish Orphan Biovitrum: Elocta Approved in Kuwait For The Treatment Of Hemophilia A     11/21/2016
CSL Behring Release: AFSTYLA, For Haemophilia A, Receives Positive Opinion From EMA CHMP     11/14/2016
Octapharma USA Announces Two Hemophilia A Clinical Trials To Utilize WILATE     11/14/2016
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A     7/28/2016
CSL Behring Presents Pivotal Efficacy Data For AFSTYLA In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress     7/27/2016
Sangamo (SGMO) Announces New Gene Therapy Clinical Development Program for Treatment Of Hemophilia A     7/26/2016
Alnylam (ALNY) To Report New Clinical Results With Fitusiran At The World Federation of Hemophilia 2016 World Congress     7/25/2016
Biogen (BIIB) And Sobi To Showcase Long-Term Efficacy And Safety Data From Extended Half-Life Hemophilia Therapies At World Federation Of Hemophilia 2016 World Congress     7/18/2016
Novo Nordisk A/S (NVO) To Present 28 Abstracts At The World Federation Of Hemophilia World Congress In Orlando     7/12/2016
AFSTYLA - CSL Behrings Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S.     6/20/2016
U.S. FDA Approves CSL Behring's AFSTYLA-- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A     5/27/2016
Chugai Pharma's Bispecific Antibody "ACE910/Emicizumab" Phase I Data In Patients With Hemophilia A Published In The New England Journal of Medicine Online     5/26/2016
Alnylam (ALNY) Initiates Fitusiran (ALN-AT3) Dosing In Hemophilia A And B Patients With Inhibitors In Ongoing Phase I Study     3/14/2016

//-->